Accessible Search Form           Advanced Search

10. Research and Development Contracts


NHLBI Research and Development Contract Obligations*: Fiscal Years 1995–2005

NHLBI Research and Development Contract Obligations: Fiscal Years 1995–2005

Text-only with data points

* For detailed data on contract-supported clinical trials, see Chapter 11.

NHLBI Total Research and Development Contract Obligations: Fiscal Years 1995–2005

Dollars (Thousands)
Fiscal Year
  1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Heart $ 70,178 $ 80,373 $ 84,820 $ 77,886 $ 93,270 $ 98,715 $ 125,291 $ 155,971 $ 195,425 $ 187,043 $ 181,970
Lung 15,414 21,032 18,183 13,123 25,432 23,341 10,993 16,578 11,745 14,131 20,946
Blood 40,324 19,522 18,934 25,695 15,436 21,538 24,572 26,751 20,082 25,460 27,831
Women's --- --- --- --- 63,100 57,700 59,200 59,000 63,222 58,838 37,826
    Health                      
     Initiative                      
Total $125,916 $120,927A $121,937B $116,704C $197,238D $201,294E $220,056F $258,300G $290,474H $285,472I $268,573J
A Includes Program Evaluation Assessment of $4,250,000.
B Includes Program Evaluation and IMPAC II Assessments of $8,986,000.
C Includes Program Evaluation and IMPAC II Assessments of $12,589,000.
D Includes Program Evaluation and IMPAC II Assessments of $14,904,000.
E Includes Program Evaluation and IMPAC II Assessments of $17,944,000.
F Includes Program Evaluation and IMPAC II Assessments of $24,579,000.
G Includes Program Evaluation and IMPAC II Assessments of $35,827,000.
H Includes Program Evaluation and IMPAC II Assessments of $54,550,000.
I Includes Program Evaluation and IMPAC II Assessments of $57,545,722.
J Includes Program Evaluation and IMPAC II Assessments of $64,399,000.

Back to Top

Major NHLBI Research and Development Contracts by Program

  Total Obligations
Prior to FY 2005
Total FY 2005 Obligations Total Obligations to Date
Heart and Vascular Diseases      
Atherosclerosis Risk in Communities (ARIC)
$ 118,626,131 $ 3,340,113 $121,966,244
Cardiovascular Health Study (CHS)
74,160,240 1,725,937 75,886,177
Coronary Artery Risk Development in Young Adults (CARDIA)
70,571,397 1,266,999 71,838,396
DNA Resequencing and Genotyping
4,000,000 7,000,000 11,000,000
Framingham Study
62,166,638 --- 62,166,638
Jackson Heart Study (JHS)
14,669,854 5,550,135 20,219,989
Mammalian Genotyping Service (MGS)
25,119,750 3,749,999 28,869,749
Multi-Ethnic Study of Atherosclerosis (MESA)
54,269,999 --- 54,269,999
Pediatric Circulatory Support
4,808,544 3,772,658 8,581,202
Proteomics Initiative
72,997,890 5,896,000 78,893,890
Translational Behavioral Science Research Consortium
14,312,876 6,117,693 20,430,569
Lung Diseases      
Lung Tissue Research Consortium
3,999,995 6,499,999 10,499,994
Tuberculosis Curriculum Coordinating Center
3,000,000 750,000 3,750,000
Blood Diseases and Resources      
Maintenance of NHLBI Biological Specimen Repository
5,603,820 990,522 6,594,342
Retrovirus Epidemiology Donor Study (REDS)
73,774,125 13,091,000 86,865,125

Sickle Cell Disease Health-Related Quality of Life Questionnaire

--- 584,008 584,008
Somatic Cell Therapy Processing Facilities
9,734,266 5,841,943 15,576,209

Back to Top

Heart and Vascular Diseases Program

Atherosclerosis Risk in Communities (ARIC), Initiated in Fiscal Year 1985

The ARIC program is a large-scale, long-term program that is measuring associations of CHD risk factors with atherosclerosis by race, gender, and geographic location. It focuses on early detection of CVD before symptoms, heart attacks, or strokes occur. The project consists of two groups: a community surveillance component and a cohort component from four communities. Three of the cohort components represent the racial mix of their community, whereas the fourth is exclusively black.

Obligations

Funding History:
   Fiscal Year 2005—$3,340,113
   Fiscal Years 1985–2004—$118,626,131
Total Funding to Date—$121,966,244

Current Active Organizations and Contract Numbers
  1. University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina
—HC-55015
  1. Baylor College of Medicine
    Houston, Texas
—HC-55016
  1. University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina
—HC-55018
  1. University of Minnesota, Twin Cities Minneapolis, Minnesota
—HC-55019
  1. Johns Hopkins University
    Baltimore, Maryland
—HC-55020
  1. Mississippi Medical Center
    Jackson, Mississippi
—HC-55021
  1. University of Texas Health Science Center
    Houston, Texas
—HC-55022

Cardiovascular Health Study (CHS), Initiated in Fiscal Year 1988

The CHS is a population-based, longitudinal study of risk factors for the development and progression of CHD and stroke in elderly adults. Specific objectives for this phase of the project include identifying risk association with clinical disease by accumulation of events; determining whether presence or progression of subclinical disease (abnormalities detected noninvasively without signs or symptoms) are better predictors of clinical disease than traditional risk factors; identifying determinants of change in subclinical disease; and identifying characteristics of subgroups at low risk for developing CVD (in whom preventive measures may be unnecessary). Minority representation is sufficient to assess black–white differences.

Obligations

Funding History:
   Fiscal Year 2005—$1,725,937
   Fiscal Years 1988–2004—$74,160,240
Total Funding to Date—$75,886,177

Current Active Organizations and Contract Numbers
  1. Johns Hopkins University
    Baltimore, Maryland
—HC-15103
  1. University of Washington
    Seattle, Washington
—HC-55222
  1. University of Washington
    Seattle, Washington
—HC-85079
  1. Wake Forest University
    Winston-Salem, North Carolina
—HC-85080
  1. Johns Hopkins University
    Baltimore, Maryland
—HC-85081
  1. University of Pittsburgh
    Pittsburgh, Pennsylvania
—HC-85082
  1. University of California, Davis
    Davis, California
—HC-85083
  1. University of Vermont
    Burlington, Vermont
—HC-85086

Coronary Artery Risk Development in Young Adults (CARDIA), Initiated in Fiscal Year 1984

The purpose of this study is to increase understanding of contributors to changes in CVD risk factors that occur during the critical years of transition from adolescence through young adulthood to middle age in a cohort of black and white young adults, aged 18 to 30 years in 1985–1986. Currently, CARDIA is addressing questions about lifestyle/psychosocial/socioeconomic risk factors, race, genes, and inflammation in relation to subclinical CVD.

Obligations

Funding History:
   Fiscal Year 2005—$1,266,999
   Fiscal Years 1984–2004—$70,571,397
Total Funding to Date—$71,838,396

Current Active Organizations and Contract Numbers
  1. New England Medical Center Hospitals, Inc.
    Boston, Massachusetts
—HC-45204
  1. Wake Forest University Health Sciences
    Winston-Salem, North Carolina
—HC-45205
  1. University of Alabama at Birmingham
    Birmingham, Alabama
—HC-48047
  1. University of Minnesota, Twin Cities
    Minneapolis, Minnesota
—HC-48048
  1. Northwestern University
    Chicago, Illinois
—HC-48049
  1. Kaiser Permanente Division of Research
    Oakland, California
—HC-48050
  1. University of Alabama at Birmingham
    Birmingham, Alabama
—HC-95095

DNA Resequencing and Genotyping, Initiated in Fiscal Year 2004

The purpose of this program is to obtain rapid, reliable, and cost-efficient DNA sequencing and genotyping of candidate genomic regions potentially important in the disease pathways of heart, lung, and blood diseases and sleep disorders. This information will assist ongoing investigations of genetic components involved in the causes, variable outcome, and progression of the diseases and disorders.

Obligations

Funding History:
   Fiscal Year 2005—$7,000,000
   Fiscal Year 2004—$4,000,000
Total Funding to Date—$11,000,000

Current Active Organizations and Contract Numbers
  1. Constella Group, Inc.
    Bethesda, Maryland
—HV-48193
  1. University of Washington
    Seattle, Washington
—HV-48194
  1. Johns Hopkins University
    Baltimore, Maryland
—HV-48195
  1. Center for the Advancement of Genetics, Inc.
    Rockville, Maryland
—HV-48196

Back to Top

Framingham Study

The orginal Framingham Study was designed as a longitudinal investigation of constitutional and environmental factors influencing the development of CVD in individuals free of these conditions at the outset. Of the original 5,209 subjects, about 500 members remain alive. In 1971, the Framingham Offspring Study was initiated to assess familial and genetic factors associated with CHD. More than 5,000 offspring (and their spouses) were included. A third-generation cohort consisting of 3,500 grandchildren has been added to permit examination of numerous hypotheses about the familial clustering of CVD and CVD risk factors. Additional goals include identifying new risk factors for cardiovascular, lung, and blood diseases and developing new imaging tests that can detect very early stages of coronary atherosclerosis in otherwise healthy adults.

Obligations

Funding History:
   Fiscal Year 2005—$0
   Fiscal Years 1983–2004—$62,166,638
Total Funding to Date—$62,166,638

Current Active Organization and Contract Number
  1. Boston University Medical Center
    Boston, Massachusetts
—HC-25195

Jackson Heart Study (JHS), Initiated in Fiscal Year 1998

The JHS is a single-site epidemiologic study of CVD in blacks, similar to established studies in Framingham, Massachusetts, and Honolulu, Hawaii, with primary goals of identifying risk factors for development and progression of CVD; enhancing recruitment, cohort retention, and scientific productivity of the existing Jackson site of the ARIC study; building research capabilities at minority institutions; developing partnerships between minority and majority institutions; and expanding minority investigator participation in large-scale epidemiologic studies.

Obligations

Funding History:
   Fiscal Year 2005—$5,550,135*
   Fiscal Years 1998–2004—$14,669,854
Total Funding to Date—$20,219,989

Current Active Organizations and Contract Numbers
  1. Jackson State University
    Jackson, Mississippi
—HC-95170
  1. Mississippi Medical Center
    Jackson, Mississippi
—HC-95171
  1. Tougaloo College
    Tougaloo, Mississippi
—HC-95172

Mammalian Genotyping Service (MGS), Initiated in Fiscal Year 1994

The MGS provides genotyping to meritorious projects involving humans, mice, rats, zebrafish, and dogs in all disease areas. It provides genome-wide screens, using short tandem repeat polymorphisms, to assist in finding genes associated with health and disease. Currently, the capacity of the MGS is 7.7 million genotypes per year.

Obligations

Funding History:
   Fiscal Year 2005—$3,749,999
   Fiscal Years 1994–2004—$25,119,750
Total Funding to Date—$28,869,749

Current Active Organization and Contract Number
  1. Marshfield Medical Research and Educational Foundation
    Marshfield, Wisconsin
—HV-48141

Multi-Ethnic Study of Atherosclerosis (MESA), Initiated in Fiscal Year 1999

The purpose of this study is to investigate the prevalence, correlates, and progression of subclinical CVD, i.e., disease detected noninvasively before it has produced clinical signs and symptoms, in a population that is 38 percent white, 28 percent black, 22 percent Hispanic, and 12 percent Asian.

Obligations

Funding History:
   Fiscal Year 2005—$0
   Fiscal Years 1999–2004—$54,269,999
Total Funding to Date—$54,269,999

Current Active Organizations and Contract Numbers
  1. University of Washington
    Seattle, Washington
—HC-95159
  1. University of California, Los Angeles
    Los Angeles, California
—HC-95160
  1. Columbia University
    New York, New York
—HC-95161
  1. Johns Hopkins University
    Baltimore, Maryland
—HC-95162
  1. University of Minnesota, Twin Cities
    Minneapolis, Minnesota
—HC-95163
  1. Northwestern University
    Chicago, Illinois
—HC-95164
  1. Wake Forest University
    Winston-Salem, North Carolina
—HC-95165
  1. University of Vermont
    Colchester, Vermont
—HC-95166
  1. New England Medical Center
    Boston, Massachusetts
—HC-95167
  1. Johns Hopkins University
    Baltimore, Maryland
—HC-95168
  1. Harbor-UCLA Research and Education Institute
    Los Angeles, California
—HC-95169

Pediatric Circulatory Support, Initiated in Fiscal Year 2004

The purpose of this program is to establish multidisciplinary teams to develop innovative circulatory assist devices or other bioengineered systems for infants and children with congenital and acquired CVD who experience cardiopulmonary failure and circulatory collapse.

Obligations

Funding History:
   Fiscal Year 2005—$3,772,658
   Fiscal Year 2004—$4,808,544
Total Funding to Date—$8,581,202

Current Active Organizations and Contract Numbers
  1. Cleveland Clinic Lerner College of Medicine
    Cleveland, Ohio
—HV-48188
  1. Ension, Inc.
    Pittsburgh, Pennsylvania
—HV-48189
  1. Jarvik Heart, Inc.
    New York, New York
—HV-48190
  1. Pennsylvania State University
    Hershey, Pennsylvania
—HV-48191
  1. University of Pittsburgh
    Pittsburgh, Pennsylvania
—HV-48192

Back to Top

Proteomics Initiative, Initiated in Fiscal Year 2002

The purpose of this program is to establish highly interactive, multidisciplinary centers to enhance and develop innovative proteomic technologies directed to relevant biologic questions associated with heart, lung, blood, and sleep health and disease. Scientists will focus on the cells’ protein machinery directed toward understanding the molecular basis of the causes and progression of heart, lung, and blood diseases and sleep disorders and identifying targets for therapeutic interventions.

Obligations

Funding History:
   Fiscal Year 2005—$5,896,000
   Fiscal Years 2002–2004—$72,997,890
Total Funding to Date—$78,893,890

Current Active Organizations and Contract Numbers
  1. Boston University
    Boston, Massachusetts
—HV-28178
  1. Institute for Systems Biology
    Seattle, Washington
—HV-28179
  1. Johns Hopkins University
    Baltimore, Maryland
—HV-28180
  1. Medical University of South Carolina
    Charleston, South Carolina
—HV-28181
  1. Medical College of Wisconsin
    Milwaukee, Wisconsin
—HV-28182
  1. Stanford University
    Stanford, California
—HV-28183
  1. University of Texas
    Galveston, Texas
—HV-28184
  1. University of Texas Southwestern Medical Center
    Dallas, Texas
—HV-28185
  1. Yale University
    New Haven, Connecticut
—HV-28186
  1. Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Rockville, Maryland
—HV-28187

Translational Behavioral Science Research Consortium, Initiated in Fiscal Year 2002

The purpose of this program is to establish a consortium of interdisciplinary basic and applied social scientists to conduct research related to developing and testing theories from the behavioral or social sciences concerning cognitive, affective, motivational, developmental, and other factors and processes underlying human behavior. Acquired knowledge will be used to develop and test methods to encourage individuals to adopt and maintain a healthy lifestyle and manage behavioral risk factors for heart, lung, and blood diseases and sleep disorders.

Obligations

Funding History:
   Fiscal Year 2005—$6,117,693
   Fiscal Years 2002–2004—$14,312,876
Total Funding to Date—$20,430,569

Current Active Organizations and Contract Numbers
  1. Weill Medical College of Cornell University
    New York, New York
—HC-25196
  1. Mount Sinai School of Medicine
    New York, New York
—HC-25197

Lung Diseases Program

Lung Tissue Research Consortium, Initiated in Fiscal Year 2004

The purpose of this program is to establish a consortium for collecting lung tissues and preparing and distributing them for research. Scientists seek to improve management of lung diseases by increasing understanding of the pathogenetic mechanisms of lung diseases through molecular histopathological studies on tissues with and without disease. Primary emphases are on COPD and idiopathic pulmonary fibrosis.

Obligations

Funding History:
   Fiscal Year 2005—$6,499,999
   Fiscal Year 2004—$3,999,995
Total Funding to Date—$10,499,994

Current Active Organizations and Contract Numbers
  1. Mayo Clinic College of Medicine
    Rochester, New York
—HR-46158
  1. University of Colorado Health Science Center
    Denver, Colorado
—HR-46159
  1. University of Colorado Health Science Center
    Denver, Colorado
—HR-46160
  1. Mayo Clinic College of Medicine
    Rochester, New York
—HR-46161
  1. University of Michigan
    Ann Arbor, Michigan
—HR-46162
  1. University of Pittsburgh
    Pittsburgh, Pennsylvania
—HR-46163
  1. Clinical Trials and Survey Corporation
    Baltimore, Maryland
—HR-46164

Tuberculosis Curriculum Coordinating Center, Initiated in Fiscal Year 2003

The purpose of this program is to establish a consortium of five Tuberculosis Curriculum Centers to strengthen and increase access to the best ongoing educational and training opportunities in TB for medical, nursing, and allied health schools, especially those that provide primary care to communities where TB is endemic and the population is at high risk.

Obligations

Funding History:
   Fiscal Year 2005—$750,000
   Fiscal Years 2003–2004—$3,000,000
Total Funding to Date—$3,750,000

Current Active Organization and Contract Number
  1. University of California, San Diego
    La Jolla, California
—HR-36157

Blood Diseases and Resources Program

Maintenance of NHLBI Biological Specimen Repository, Initiated in Fiscal Year 1998

The purpose of this project is to establish an NHLBI Biological Specimen Repository for blood specimens from Institute-supported research. The Repository monitors storage, labeling, and testing of the specimens, as well as administers safe shipment of precise sample aliquots to approved investigators for future studies.

Obligations

Funding History:
   Fiscal Year 2005—$990,522
   Fiscal Years 1998–2004—$5,603,820
Total Funding to Date—$6,594,342

Current Active Organization and Contract Number
  1. BBI-Biotech Research Laboratories, Inc.
    Gaithersburg, Maryland
—HB-87144

Back to Top

Retrovirus Epidemiology Donor Study (REDS), Initiated in Fiscal Year 1989

This program was established to determine the prevalence of retrovirus positivity in blood donors, a majority of whom are minority. Researchers are evaluating the demographic, risk factor, and behavioral characteristics of blood donors with high risks who continue to donate. A blood specimen repository also is being established as a mechanism for evaluating new tests for known viruses and as a sentinel for as-yet-unrecognized viruses.

Obligations

Funding History:
   Fiscal Year 2005—$13,091,000
   Fiscal Years 1989–2004—$73,774,125
Total Funding to Date—$86,865,125

Current Active Organizations and Contract Numbers
  1. University of California, San Francisco
    San Francisco, California
—HB-47114
  1. Blood Center of Southeastern Wisconsin
    Milwaukee, Wisconsin
—HB-47168
  1. American Red Cross Blood Services
    Dedham, Massachusetts
—HB-47169
  1. Emory University
    Atlanta, Georgia
—HB-47170
  1. University of Cincinnati
    Cincinnati, Ohio
—HB-47171
  1. Institute for Transfusion Medicine
    Pittsburgh, Pennsylvania
—HB-47172
  1. University of California, San Francisco
    San Francisco, California
—HB-47174
  1. Westat, Inc.
    Rockville, Maryland
—HB-47175
  1. Oklahoma Blood Institute
    Oklahoma City, Oklahoma
—HB-97078
  1. Westat, Inc.
    Rockville, Maryland
—HB-97082

Sickle Cell Disease Health-Related Quality of Life Questionnaire, Initiated in Fiscal Year 2005

The purpose of this project is to develop a psychometrically sound and clinically useful health-related quality of life instrument and related materials for use in sickle cell clinical trials and outcomes research among adults with SCD, and to assist researchers who are early users of the instrument and materials.

Obligations

Funding History:
   Fiscal Year 2005—$584,008
Total Funding To Date—$584,008

Current Active Organization and Contract Number
  1. American Institutes for Research Health Program
    Silver Spring, Maryland
—HL-54264

Somatic Cell Therapy Processing Facilities, Initiated in Fiscal Year 2003

This program is designed to develop novel somatic cellular therapies in areas ranging from basic science through animal studies to proof-of-principle and eventually human trials for heart, lung, and blood diseases and sleep disorders. The goal is to provide rapid, safe translation of basic research ideas into clinical practice.

Obligations

Funding History:
   Fiscal Year 2005—$5,841,943
   Fiscal Years 2003–2004—$9,734,266
Total Funding to Date—$15,576,209

Current Active Organizations and Contract Numbers
  1. Baylor College of Medicine
    Houston, Texas
—HB-37163
  1. University of Minnesota, Twin Cities
    Minneapolis, Minnesota
—HB-37164
  1. University of Pittsburgh
    Pittsburgh, Pennsylvania
—HB-37165
  1. The EMMES Corporation
    Rockville, Maryland
—HB-37166

Back to Top

« Back

Next »

Fact Book Table of Contents

Twitter iconTwitterimage of external icon Facebook iconFacebookimage of external icon YouTube iconYouTubeimage of external icon Google+ iconGoogle+image of external icon